Listed

TG Therapeutics, Inc.

TGTXNasdaqCIK 1001316HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$240.3mRevenue, Q2 FY2026, three months to 2026-06-30$240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$240.3mRevenue, Q2 FY2026, three months to 2026-06-30$240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure+70.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin9.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure−15.7 pts on a year earlier
  • Net margin3.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $7.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure−16.7 pts on a year earlier
  • Diluted EPS$0.05Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure−70.6% on a year earlier
  • Free cash flow$39.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $39.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Capital expenditure: $293.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Report this figure+427.0% on a year earlier

Last eight quarters

Full statements
Revenue$240.3mOperating margin 9.0%
Diluted EPS$0.05, Q2 FY2026
Free cash flow$39.0m, Q2 FY2026
TG Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m83.9Revenue, Q3 FY2024, three months to 2024-09-30$83.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure108Revenue, Q4 FY2024, three months to 2024-12-31$108.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure121Revenue, Q1 FY2025, three months to 2025-03-31$120.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure141Revenue, Q2 FY2025, three months to 2025-06-30$141.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure162Revenue, Q3 FY2025, three months to 2025-09-30$161.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure193Revenue, Q4 FY2025, three months to 2025-12-31$192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure205Revenue, Q1 FY2026, three months to 2026-03-31$204.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure240Revenue, Q2 FY2026, three months to 2026-06-30$240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%14.8%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $12.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Revenue: $83.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure27.7%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $29.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Revenue: $108.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure7.1%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $8.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Revenue: $120.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure24.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $34.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $141.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure18.2%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $29.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Revenue: $161.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure26.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $50.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Revenue: $192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure17.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $34.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Revenue: $204.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure9.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure
Net margin%4.6%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Revenue: $83.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure21.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $23.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Revenue: $108.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure4.2%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $120.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure20.0%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $28.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $141.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure241.7%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $390.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Revenue: $161.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figure12.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Revenue: $192.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure9.7%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $204.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure3.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $7.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Revenue: $240.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure
Diluted EPS$ per share0.02Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figurenot reported (Diluted EPS not reported)0.03Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure0.17Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure2.43Diluted EPS, Q3 FY2025, three months to 2025-09-30$2.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001437749-25-033363.Report this figurenot reported (Diluted EPS not reported)0.12Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure0.05Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001437749-26-025955.Report this figure
Free cash flow$m(12.2)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$12.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001437749-25-033363. Derived: 9-month figure less the 6-month figure.Capital expenditure: $24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001437749-25-033363. Derived: 9-month figure less the 6-month figure.Report this figure(25.7)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$25.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Capital expenditure: $21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure(28.7)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$28.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Capital expenditure: $25.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure7.4Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Capital expenditure: $42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Report this figure(23.2)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$23.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001437749-25-033363. Derived: 9-month figure less the 6-month figure.Capital expenditure: $80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001437749-25-033363. Derived: 9-month figure less the 6-month figure.Report this figure19.6Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Capital expenditure: $67.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001437749-26-006133. Derived: 12-month figure less the 9-month figure.Report this figure(17.9)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$17.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Capital expenditure: $51.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001437749-26-015246.Report this figure39.0Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $39.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Capital expenditure: $293.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001437749-26-025955. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$616.3mOperating margin 20.0%
Diluted EPS$2.77, FY2025
Free cash flow−$25.0m, FY2025
TG Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m6.7Revenue, FY2021, twelve months to 2021-12-31$6.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006144.Report this figure2.8Revenue, FY2022, twelve months to 2022-12-31$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001437749-25-005908.Report this figure234Revenue, FY2023, twelve months to 2023-12-31$233.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure329Revenue, FY2024, twelve months to 2024-12-31$329.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure616Revenue, FY2025, twelve months to 2025-12-31$616.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(5154.3%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$344.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0001437749-24-006144.Revenue: $6.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006144.Report this figure(7839.0%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$218.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-03, accession 0001437749-25-005908.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001437749-25-005908.Report this figure8.8%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $20.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $233.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure12.7%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $41.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $329.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure20.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $123.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $616.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure
Net margin%(5204.1%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$348.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0001437749-24-006144.Revenue: $6.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001437749-24-006144.Report this figure(8036.3%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$223.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-03, accession 0001437749-25-005908.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-03, accession 0001437749-25-005908.Report this figure5.4%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $233.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure7.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $329.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure72.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $447.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001437749-26-006133.Revenue: $616.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure
Diluted EPS$ per share(2.63)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0001437749-24-006144.Report this figure(1.65)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-03, accession 0001437749-25-005908.Report this figure0.09Diluted EPS, FY2023, twelve months to 2023-12-31$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure0.15Diluted EPS, FY2024, twelve months to 2024-12-31$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure2.77Diluted EPS, FY2025, twelve months to 2025-12-31$2.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure
Free cash flow$m(296)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$295.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0001437749-24-006144.Capital expenditure: $401.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0001437749-24-006144.Report this figure(176)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$176.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-03, accession 0001437749-25-005908.Capital expenditure: $14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-03, accession 0001437749-25-005908.Report this figure(31.4)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$31.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001437749-26-006133.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure(40.6)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$40.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001437749-26-006133.Capital expenditure: $45.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure(25.0)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001437749-26-006133.Capital expenditure: $214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001437749-26-006133.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding TG Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$1.21bn22,050,045Reduced−202,885
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$437.5m7,963,266Reduced−310,713
STATE STREET CORP2026-06-30$427.8m7,786,471Reduced−863,295
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$337.8m6,149,403Reduced−453,855
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$200.1m3,642,216Added+142,300
D. E. Shaw & Co., Inc.2026-06-30$186.8m3,400,808Added+2,810,761
Soleus Capital Management, L.P.2026-06-30$160.9m2,927,895Reduced−1,101,424
Clearbridge Investments, LLC2026-06-30$145.6m2,650,192Reduced−560,738
CONGRESS ASSET MANAGEMENT CO2026-06-30$142.9m2,600,123Added+432,042
TWO SIGMA INVESTMENTS, LP2026-06-30$135.6m2,468,971Added+926,659

Recent filings

All 700 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

TG Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0517:01 ET10-QQuarterly reportPeriod 2026-06-300001437749-26-025955
2026-08-0307:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-025304
2026-06-1216:32 ET8-K5.07 Shareholder vote results0001437749-26-020491
2026-06-0307:34 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-019262
2026-05-2716:34 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001437749-26-018586
2026-05-0617:00 ET10-QQuarterly reportPeriod 2026-03-310001437749-26-015246
2026-05-0607:25 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-015013
2026-04-3016:31 ETDEF 14AProxy statementPeriod 2026-06-110001437749-26-014233
2026-03-2016:33 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001437749-26-009253
2026-02-2717:05 ET10-KAnnual reportPeriod 2025-12-310001437749-26-006133

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 27, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1001316
Tickers
TGTX
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
MANHATTAN PHARMACEUTICALS INC (to 2012-04-27); ATLANTIC TECHNOLOGY VENTURES INC (to 2003-03-10); ATLANTIC PHARMACEUTICALS INC (to 2000-02-04)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. Listed shows no prices and gives no investment advice.